Dr. Stephanie Venn-Watson

idea of um all saturated fats like are bad and that we have one that's essential so it's like how do we get it back into our diet um so there's you know a lot of uh you could feel right the urgency around this movement um the reason for the book um is really to help increase education and let's have the conversations around so we can't explain it away anymore so you know

idea of um all saturated fats like are bad and that we have one that's essential so it's like how do we get it back into our diet um so there's you know a lot of uh you could feel right the urgency around this movement um the reason for the book um is really to help increase education and let's have the conversations around so we can't explain it away anymore so you know

So with regard to, there was a second study in Singapore, and that's the one I had mentioned. That was also fatty liver disease, women with fatty liver disease. And it showed that it lowered LDL cholesterol and then improved the gut microbiome. That was an interesting study because what they did for this clinical trial, and this was also a controlled clinical trial,

So with regard to, there was a second study in Singapore, and that's the one I had mentioned. That was also fatty liver disease, women with fatty liver disease. And it showed that it lowered LDL cholesterol and then improved the gut microbiome. That was an interesting study because what they did for this clinical trial, and this was also a controlled clinical trial,

So with regard to, there was a second study in Singapore, and that's the one I had mentioned. That was also fatty liver disease, women with fatty liver disease. And it showed that it lowered LDL cholesterol and then improved the gut microbiome. That was an interesting study because what they did for this clinical trial, and this was also a controlled clinical trial,

The control group was one that went on a hypocaloric diet. Low-calorie diet. Yeah, exactly, like 1,000 calories per day. That would be tough to sustain. That was the first group. The second group was a low-calorie plus Mediterranean guidelines, which both of those have been shown to help with fatty liver disease metabolism.

The control group was one that went on a hypocaloric diet. Low-calorie diet. Yeah, exactly, like 1,000 calories per day. That would be tough to sustain. That was the first group. The second group was a low-calorie plus Mediterranean guidelines, which both of those have been shown to help with fatty liver disease metabolism.

The control group was one that went on a hypocaloric diet. Low-calorie diet. Yeah, exactly, like 1,000 calories per day. That would be tough to sustain. That was the first group. The second group was a low-calorie plus Mediterranean guidelines, which both of those have been shown to help with fatty liver disease metabolism.

Even better. Even better. You're spot on. And then the third was low-calorie Mediterranean plus C15 supplementation. So it was a big lift to ask of C15. In those groups, not only did the third group, the C15 supplementation result in lower LDL cholesterol and improved gut microbiome,

Even better. Even better. You're spot on. And then the third was low-calorie Mediterranean plus C15 supplementation. So it was a big lift to ask of C15. In those groups, not only did the third group, the C15 supplementation result in lower LDL cholesterol and improved gut microbiome,

Even better. Even better. You're spot on. And then the third was low-calorie Mediterranean plus C15 supplementation. So it was a big lift to ask of C15. In those groups, not only did the third group, the C15 supplementation result in lower LDL cholesterol and improved gut microbiome,

But it also had the lowest, it had the greatest loss of liver fat, the greatest loss of body fat, the greatest glucose improvements, but it was trending. It was not statistically significant. You just kind of saw the step. But again, it was 12 weeks. And so the question is dosing, timing, things like that. In numerous studies, so these meta-analyses, studies of studies that prospectively follow

But it also had the lowest, it had the greatest loss of liver fat, the greatest loss of body fat, the greatest glucose improvements, but it was trending. It was not statistically significant. You just kind of saw the step. But again, it was 12 weeks. And so the question is dosing, timing, things like that. In numerous studies, so these meta-analyses, studies of studies that prospectively follow

But it also had the lowest, it had the greatest loss of liver fat, the greatest loss of body fat, the greatest glucose improvements, but it was trending. It was not statistically significant. You just kind of saw the step. But again, it was 12 weeks. And so the question is dosing, timing, things like that. In numerous studies, so these meta-analyses, studies of studies that prospectively follow

Thousands of people over decades, numerous studies have consistently shown people with higher C15, just like we saw in the dolphins, lower risk of developing type 2 diabetes, of heart disease, specifically coronary heart disease, of developing fatty liver disease and certain types of cancers, specifically a lot of work on colorectal cancer.

Thousands of people over decades, numerous studies have consistently shown people with higher C15, just like we saw in the dolphins, lower risk of developing type 2 diabetes, of heart disease, specifically coronary heart disease, of developing fatty liver disease and certain types of cancers, specifically a lot of work on colorectal cancer.

Thousands of people over decades, numerous studies have consistently shown people with higher C15, just like we saw in the dolphins, lower risk of developing type 2 diabetes, of heart disease, specifically coronary heart disease, of developing fatty liver disease and certain types of cancers, specifically a lot of work on colorectal cancer.

This is why with all these different aspects of the data from epidemiological data, clinical trials, mechanisms of action, in vivo efficacy studies, this is why Nick, Dr. Nick Shork, he was at ARDD, which is one of the world's leading anti-aging therapeutics meetings. He was in Copenhagen last year, and he presented C15. He said, listen, I've seen every longevity molecule before.

This is why with all these different aspects of the data from epidemiological data, clinical trials, mechanisms of action, in vivo efficacy studies, this is why Nick, Dr. Nick Shork, he was at ARDD, which is one of the world's leading anti-aging therapeutics meetings. He was in Copenhagen last year, and he presented C15. He said, listen, I've seen every longevity molecule before.

This is why with all these different aspects of the data from epidemiological data, clinical trials, mechanisms of action, in vivo efficacy studies, this is why Nick, Dr. Nick Shork, he was at ARDD, which is one of the world's leading anti-aging therapeutics meetings. He was in Copenhagen last year, and he presented C15. He said, listen, I've seen every longevity molecule before.